AVITA Drug Patent Profile

When do Avita patents expire, and when can generic versions of Avita launch?

Avita is a drug marketed by Mylan Pharms Inc and Rising and is included in two NDAs.

The generic ingredient in AVITA is tretinoin. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the tretinoin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Avita

A generic version of AVITA was approved as tretinoin by PADAGIS US on December 24^th, 1998.

Summary for AVITA

US Patents:	0
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Drug Prices:	Drug price information for AVITA
What excipients (inactive ingredients) are in AVITA?	AVITA excipients list
DailyMed Link:	AVITA at DailyMed

See drug prices for AVITA

See drug sales revenues for AVITA

US Patents and Regulatory Information for AVITA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan Pharms Inc	AVITA	tretinoin	CREAM;TOPICAL	020404-003	Jan 14, 1997	AB	RX	No	No
Rising	AVITA	tretinoin	GEL;TOPICAL	020400-001	Jan 29, 1998		DISCN	No	No

Expired US Patents for AVITA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mylan Pharms Inc	AVITA	tretinoin	CREAM;TOPICAL	020404-003	Jan 14, 1997	4,971,800
Mylan Pharms Inc	AVITA	tretinoin	CREAM;TOPICAL	020404-003	Jan 14, 1997	5,045,317

International Patents for AVITA

See the table below for patents covering AVITA around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2065912
Austria	115553
Greece	3015410
Ireland	66710	Compositions for enhancing the cutaneous penetration of pharmacologically active agents
Israel	87133	POLYOXYALKYLENE-POLYURETHANE CONTAINING COMPOSITION FOR ENHANCING THE CUTANEOUS PENETRATION OF PHARMACOLOGICALLY ACTIVE COMPOUNDS
European Patent Office	0299758	Compositions augmentant la pénétration cutanée d'agents pharmaceutiquement actifs. (Compositions for enhancing the cutaneous penetration of pharmacologically active agents.)

Supplementary Protection Certificates for AVITA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1304992	PA2013025,C1304992	Lithuania		PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
0617614	SPC/GB01/014	United Kingdom		PRODUCT NAME: ALITRETINOIN; REGISTERED: UK EU/1/00/149/001 20001018
1304992	122013000081	Germany		PRODUCT NAME: CLINDAMYCIN (ALS CLINDAMYCIN-PHOSPHAT) UND TRETINOIN; NAT. REGISTRATION NO/DATE: 85210.00.00 20130611; FIRST REGISTRATION: IRLAND PA1332/043/001 20130322
1304992	2013/044	Ireland		PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
0617614	2001/009	Ireland		PRODUCT NAME: PANRETIN-ALITRETINOIN
1304992	PA2013025	Lithuania		PRODUCT NAME: CLINFAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323

AVITA Pharmaceutical: Market Dynamics and Financial Trajectory

Last updated: February 20, 2026

What is AVITA Pharmaceutical’s current market position?

AVITA Pharmaceutical specializes in developing regenerative medicines, primarily focusing on skin and wound management products. Its key marketed drug is RECELL, a device used to treat burn injuries and other skin defects. The product has received FDA approval and is marketed in the U.S. and select international markets.

Historically, the company’s revenue has relied heavily on RECELL sales, with limited diversification. The firm’s market valuation fluctuates based on clinical trial progress, regulatory updates, and adoption in clinical settings. As of Q4 2022, AVITA's market cap was approximately USD 470 million.

How does the competitive landscape influence AVITA’s market prospects?

The regenerative skin product market faces competition from both established large pharmaceutical companies and smaller biotech firms. Key competitors include:

• Cytograft Tissue Engineering
• Smith & Nephew
• Integra LifeSciences

Market entry barriers include regulatory approval processes, clinical adoption rates, and reimbursement policies. AVITA’s product differentiation hinges on RECELL’s ability to reduce hospitalization and operative time compared to traditional grafting techniques.

What are the regulatory trends affecting AVITA?

Regulatory authorities, primarily the FDA, influence AVITA’s trajectory through approval processes, post-market surveillance, and reimbursement pathways.

• FDA approval was granted in 2018 for RECELL as an autologous cell harvesting device.
• Increased focus on real-world evidence and post-market data may impact future approvals or label expansions.
• Reimbursement policies, including Medicare and private payers, determine the product’s market penetration. Currently, reimbursement varies across regions, affecting sales growth.

How do clinical data and adoption rates shape revenue prospects?

Clinical trials and real-world evidence demonstrating RECELL’s efficacy and safety have facilitated market penetration. Positive data on reduced grafting procedures and shorter hospital stays support increased adoption.

• In 2021, AVITA announced data indicating RECELL reduces operative time by approximately 30% versus traditional methods.
• Limiting factors include clinicians’ familiarity with standard techniques and the cost of the device relative to conventional treatments.

Market adoption remains moderate with expanding use cases, such as chronic wounds and dermatology, pending further data.

How are financial metrics trending?

AVITA’s financial profile reflects early-stage commercialization:

Metric	2021	2022	Q1 2023
Revenue (USD million)	3.1	4.2	1.2
Operating expenses (USD million)	8.5	9.7	2.4
Net loss (USD million)	8.2	8.9	2.3
Cash and equivalents (USD million)	24.0	22.8	21.5

Revenue growth reflects scaling efforts; however, profitability remains distant. The company is heavily reliant on ongoing funding, with a burn rate of approximately USD 2 million per month.

What is the outlook for revenue growth and profitability?

• Revenue catalysts: Expansion into new markets, adoption in chronic wound care, and diversified product pipeline.
• Risks: Competition, regulatory delays, and reimbursement hurdles could constrain revenue expansion.
• Financial trajectory: Expectations include a gradual increase in sales, potentially reaching USD 15–20 million annually by 2025 if adoption accelerates.

Profitability is unlikely before the late 2020s unless sales volume increases significantly and cost efficiencies are achieved. The firm’s current financial structure includes warrant issuance and planned equity offerings to sustain operations.

How do macro factors and policy developments influence AVITA’s prospects?

• Healthcare spending patterns influence device reimbursement rates and utilization.
• Regulatory environment, including criteria for clinical evidence and post-market surveillance, impacts product expansion.
• Global health priorities, notably burn management and wound care, drive demand for innovative regenerative products.

Government or private sector investments in regenerative medicine could accelerate AVITA’s market entry and growth.

Key Takeaways

• AVITA’s primary asset, RECELL, remains the core revenue driver, with moderate market penetration.
• Competition from established players limits early-stage growth but ongoing clinical data may improve acceptance.
• The company's financials are characterized by modest revenue growth and ongoing net losses, supported by cash reserves.
• Market expansion depends on regulatory approvals, reimbursement policies, and clinical adoption.
• Macro health policies and technological advances in regenerative medicine present both risks and opportunities.

FAQs

Q1: What is the revenue outlook for AVITA over the next five years?
Expect gradual growth, reaching USD 15–20 million annually by 2025 if market adoption accelerates.

Q2: How does reimbursement policy influence AVITA’s sales?
Reimbursement determines product affordability and clinician adoption; coverage variability affects sales volume.

Q3: What competitive advantages does RECELL have?
It reduces operative time and the need for graft harvesting, offering clinical efficiency benefits.

Q4: Are there regulatory hurdles ahead for AVITA?
Yes; expansion into new indications or markets requires additional approvals and clinical data.

Q5: How will macroeconomic factors impact AVITA’s stock valuation?
Healthcare spending, regulatory environment, and investor sentiment toward regenerative medicine influence valuation.

---

References

1. FDA. (2018). Device Approvals and Clearance. Retrieved from https://www.fda.gov

2. AVITA Pharmaceutical. (2022). Annual Report.

3. MarketWatch. (2023). AVITA Market Cap and Share Data.

4. PwC. (2021). Regenerative Medicine Market Review.

5. GlobalData. (2022). Wound Care Market Trends.